BMS renews distribution contract with Yusen Logistics

Published: 16-Aug-2011
Pharmaceutical Logistics

For the pan-European distribution of OTC and prescription drugs

Pharmaceutical manufacturer Bristol-Myers Squibb (BMS) has renewed its pan-European distribution contract with Yusen Logistics for its over-the-counter and prescription drugs.

The two companies have been working together since 2007 when Yusen was appointed to create a lean supply chain for BMS.

BMS co-loads product from multiple plants, as well as with other pharmaceutical firms using Yusen’s European pharmaceutical distribution network, which is known as its ‘superhighway’.

The Yusen operation involves temperature-controlled distribution of more than 120,000 pallets of product per annum from BMS' six manufacturing plants in France, Italy and Ireland. It also collects from third party manufacturers elsewhere in Europe and delivers to more than 80 points in 35 countries throughout Europe.

Eric Plouffe, EMEA associate director, Transportation, Compliance & Logistics Planning at BMS, said: ‘The superhighway provides a temperature-controlled, quality-approved secure solution which meets the ever-increasing regulatory requirements demanded by European Health Agencies. Extending our partnership will enable us to continue to derive benefits within our supply chain while also enjoying additional cost savings.’

All Yusen vehicles used for the service are temperature controlled and have GPS tracking. Additional controls are in place for narcotics to ensure safe delivery.

Looking to the future, Yusen and BMS will continue to work together to create further efficiencies through Yusen's high security network.

See more

You may also like

Research & Development

Oxford BioTherapeutics signs T-cell engager collaboration with Bristol Myers Squibb for solid tumour targets

Read more
The company has entered a multi-year collaboration with BMS to discover and develop next-generation T-cell engager therapies for solid tumours using its OGAP-Verify platform, marking the company's third major pharma partnership in twelve months following deals with GSK and Roche

Trending Articles

  1. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  2. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  3. Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
  4. Cleanroom Technology Awards 2026: The winners The winners of the Cleanroom Technology Awards 2026 have now been revealed. The 2026 edition brought together some of the most forward-thinking organisations in the industry, recognising innovation, technical excellence, and impactful advancements across cleanroom design, operation, and technology
  5. Freudenberg Medical launches CleanAssure ISO Class 5 cleanroom service for sterile single-use biopharma assemblies CleanAssure is an ISO Class 5 controlled cleanroom service delivering washed, dried and gamma-sterilised single-use assemblies to biopharmaceutical customers, addressing industry challenges around cleaning validation and contamination risk

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

Oxford BioTherapeutics signs T-cell engager collaboration with Bristol Myers Squibb for solid tumour targets

The company has entered a multi-year collaboration with BMS to discover and develop next-generation T-cell engager therapies for solid tumours using its OGAP-Verify platform, marking the company's third major pharma partnership in twelve months following deals with GSK and Roche
Logistics

YLGM and AGL officially launch “Yusen Africa” joint venture in Nairobi

Yusen Logistics Global Management and Africa Global Logistics have inaugurated Yusen Africa in Kenya, establishing a new East African logistics hub to strengthen regional trade corridors and deliver integrated supply chain solutions
Finance

Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb

The biotech company focuses on developing new drugs for fibrotic and other inflammatory diseases
Design & Build

Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy

Facility in Anagni is equipped with oral solid, biologics, and sterile product manufacturing and packaging capabilities
Research & Development

Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies

Biocartis Group has signed a collaboration agreement with Bristol-Myers Squibb to register and use the Idylla MSI test in connection with immuno-oncology therapies
Media

BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants

Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Finance

Bristol-Myers Squibb to merge with Celgene in multimillion deal

Transaction will see a combined pharmaceutical company in pole position within the immuno-oncology and the treatment of blood cancers market
Subscribe now